Skip to main content

Harvard Bio Revenues Up 10 Percent, Profit Slips

NEW YORK (GenomeWeb News) - Harvard Bioscience yesterday said first-quarter revenue rose 10 percent as R&D spending increased 12 percent, and net income slipped 8 percent.
Total receipts for the three months ended March 31, 2007, increased to $19.1 million from $17.4 million year over year.
Harvard Bio said new sales stemming from the acquisition of Anthos' washer and microplate reader assets last June contributed 8 percent of revenue growth.
Fluctuations in foreign exchange rates contributed an additional 5 percent of revenue growth, but this was offset by a 3 percent decrease in organic revenue.  
R&D spending increased to $844,000 from $751,000 in the year-ago period. 
Harvard Bio reported net income of $496,000 in the quarter compared to $540,000 in the same period last year.
The company said it had around $8.6 million in cash and equivalents as of March 31.
Looking forward, Harvard Bioscience projected second-quarter revenue to be between $19.5 million and $20.5 million, and reaffirmed its expectation for revenue between $80 million and $83.0 million for full-year 2007.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.